Markets have turned upbeat amid optimism that the 39-day US shutdown could soon come to an end, after a weekend of dealmaking in Washington. A new bill quickly advanced in a key S ...

Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.

J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer today and set a price target of $30.00. The company’s shares closed yesterday at $24.66. Take advantage of TipRanks Premium at 50% ...

Currently, the analyst consensus on Pfizer is a Hold with an average price target of $28.60, representing a 15.98% upside. In a report released today, J.P. Morgan also maintained a Hold rating on the ...

Pfizer revenue trends remained uneven in the third quarter, the company exhibited "continued cost discipline," according to ...

Revenue reported by Pfizer in Q3 2025 came in at $16.7 billion, which was another beat compared to the analysts’ estimate of ...

Analysts expect the health care company to report quarterly earnings at 64 cents per share, down from $1.06 per share in the ...

2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...

Drugmaker Pfizer ($PFE) is set to report its Q3 earnings results on November 4 before the market opens. Analysts are ...

The stock has surged roughly 157% YTD, yet both Wall Street and Seeking Alpha’s Quant Rating keep a Hold due to valuation concerns. Piper Sandler lifted its price target to $210 from ... 100% of those ...

Pfizer Inc. (NYSE:PFE) is one of the Best Stocks to Buy for High Returns Heading into 2026. On October 27, Berenberg Bank ...